Publications by authors named "Jean-Pascal H Machiels"

17Publications

Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.

Oral Oncol 2020 05 10;104:104631. Epub 2020 Mar 10.

Department of Medical Oncology, Institut Roi Albert II - Cliniques universitaires Saint-Luc, Brussels, Belgium; Institute for Clinical and Experimental Research (MIRO), Université catholique de Louvain, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2020.104631DOI Listing
May 2020

Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN).

Cancer Treat Rev 2020 Apr 14;85:101992. Epub 2020 Feb 14.

Department of Medical Oncology, Institut Roi Albert II - Cliniques universitaires Saint-Luc, Brussels, Belgium; Institute for Clinical and Experimental Research (MIRO), Université catholique de Louvain, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.101992DOI Listing
April 2020

The promise of immunostimulatory antibodies in head and neck cancer.

Lancet Oncol 2016 07 27;17(7):856-857. Epub 2016 May 27.

de Duve Institute, Université catholique de Louvain, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30106-1DOI Listing
July 2016

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.

BMC Cancer 2014 Jun 28;14:473. Epub 2014 Jun 28.

Cancer Center, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079914PMC
June 2014

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.

J Clin Oncol 2010 Jan 14;28(3):475-80. Epub 2009 Dec 14.

Baylor-Sammons/Texas Oncology Physician's Association, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.21.6994DOI Listing
January 2010

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

J Clin Oncol 2010 Jan 16;28(1):21-8. Epub 2009 Nov 16.

Medical Oncology Unit, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.23.8584
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.23.8584DOI Listing
January 2010

Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.

J Immunol 2003 Apr;170(8):4273-80

Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins, Graduate Program in Immunology, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.170.8.4273DOI Listing
April 2003

Cytokine gene-modified cell-based cancer vaccines.

Methods Mol Med 2002 ;69:233-57

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1385/1-59259-141-8:233DOI Listing
January 2003